Anti Mitochondrial Antibody

A positive anti‑mitochondrial antibody (AMA) indicates an autoimmune response against mitochondrial proteins and is most strongly linked to primary biliary cholangitis (PBC). It supports diagnosis when cholestatic liver tests are abnormal. AMAs can rarely occur with other autoimmune conditions or as false positives, so further evaluation (liver blood tests, imaging, and hepatology referral) is recommended to confirm diagnosis and guide care.

Antimitochondrial antibodies (AMA) are strongly associated with primary biliary cholangitis (PBC), an autoimmune liver disease characterized by progressive destruction of intrahepatic bile ducts leading to cholestasis, pruritus, fatigue, and eventual cirrhosis if untreated. AMA is present in about 90–95% of PBC patients and is an important diagnostic marker used alongside clinical features and cholestatic liver biochemistry.

Anti‑mitochondrial antibodies (AMA) are strongly associated with primary biliary cholangitis (PBC), an autoimmune chronic liver disease characterized by progressive destruction of intrahepatic bile ducts, cholestasis, and eventual cirrhosis. AMA positivity is present in around 90–95% of PBC cases and is an important diagnostic marker; PBC primarily affects middle‑aged women and causes fatigue, pruritus, and raised cholestatic liver enzymes.

If anti‑mitochondrial antibodies (AMA) are high, it often indicates primary biliary cholangitis (an autoimmune bile‑duct disease). You should get liver function tests (especially ALP, IgM), further autoimmune panels, and specialist referral. Early treatment (ursodeoxycholic acid), symptom management, monitoring for progression, bone health and other autoimmune conditions are recommended. Follow‑up with a hepatologist or primary care clinician is essential.

Yes — a positive anti‑mitochondrial antibody (AMA) can sometimes be incidental. Low‑titer or isolated AMA may occur in healthy people or with other autoimmune conditions and doesn’t always indicate disease. Higher AMA titers more commonly point to primary biliary cholangitis (PBC). Interpretation needs clinical context: symptoms, liver function tests, and specialist follow‑up (repeat testing, imaging, or biopsy if indicated).

Anti‑mitochondrial antibodies (AMA) are most strongly linked to primary biliary cholangitis (PBC). They also appear in PBC–autoimmune hepatitis overlap and other autoimmune liver diseases, chronic hepatitis or drug‑induced liver injury. AMAs can be detected in systemic autoimmune conditions such as Sjögren’s syndrome, systemic sclerosis, and, less commonly, rheumatoid arthritis or systemic lupus erythematosus; rare low‑titre positivity may occur in older healthy individuals.